Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 4
Submit an article Journal homepage
2,867
Views
13
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study

Johannes DrachMedical University of Vienna, Vienna General Hospital, Vienna, Austria; Correspondence[email protected]
View further author information
,
Huiqiang HuangSun Yat-sen University Cancer Center, Guangzhou, Guangdong, China; View further author information
,
Olga SamoilovaNizhniy Novgorod Region Clinical Hospital, Nizhniy Novgorod, Russian Federation; View further author information
,
Andrew BelchUniversity of Alberta, Cross Cancer Institute, Edmonton, AB, Canada; View further author information
,
Charles FarberCarol G. Simon Cancer Center, Morristown, NJ, USA; View further author information
,
André BoslyCHU Dinant-Godinne UCL Namur, Yvoir, Belgium; View further author information
,
Jan NovakCharles University in Prague, Prague, Czech Republic; View further author information
,
Jan ZauchaGdynia Oncology Center & Medical University of Gdansk, Gdynia, Poland; View further author information
,
Angela DascalescuInstitutul Regional de Oncologie Iasi, Judetul, lasi, Romania; View further author information
,
Udomsak BunworasateKing Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand; View further author information
,
Zvenyslava MasliakInstitute of Blood Pathology and Transfusion Medicine of National Academy of Medical Sciences of Ukraine, Lviv, Ukraine; View further author information
,
Kateryna VilchevskayaInstitute of Urgent and Recovery Surgery n.a V.K. Gusaka of AMS of Ukraine, Donetsk, Ukraine; View further author information
,
Tadeusz RobakMedical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland; View further author information
,
Lixia PeiJanssen Research & Development, LLC, Raritan, NJ, USA; View further author information
,
Brendan RooneyJanssen Research & Development, High Wycombe, United Kingdom; View further author information
,
Helgi van de VeldeMillennium Pharmaceuticals, Inc, Boston, MA, USA; View further author information
&
Franco CavalliOncology Institute of Southern Switzerland Ospedale San Giovanni, Bellinzona, SwitzerlandView further author information
 show all
Pages 896-903 | Received 06 Apr 2017, Accepted 06 Aug 2017, Published online: 17 Jan 2018

References

  • Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009;27:511–518.
  • Vose JM. Mantle cell lymphoma: 2013 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2013;88:1082–1088.
  • Williams ME. Transplantation for mantle cell lymphoma: is it the right thing to do? Hematology Am Soc Hematol Educ Program. 2013;2013:568–574.
  • Dreyling M, Geisler C, Hermine O, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol.2014;25 :iii83–iii92.
  • National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): B-cell Lymphomas. Version 3.2017; March 27, 2017. [cited 2017 Jun 23]. Available from: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site
  • Pham LV, Tamayo AT, Yoshimura LC, et al. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol. 2003;171:88–95.
  • Chiarle R, Budel LM, Skolnik J, et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood. 2000;95:619–626.
  • Millennium Pharmaceuticals Inc. VELCADE® (bortezomib) for injection: for subcutaneous or intravenous use, full prescribing information. Version 19; June, 2017. [cited 2017 Jun 23]. Available from: http://www.velcade.com/files/pdfs/velcade_prescribing_information.pdf
  • Velcade. Summary of Product Characteristics. Last updated 10 March, 2017. [cited 2017 Jun 23]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000539/WC500048471.pdf
  • Perez-Galan P, Roue G, Villamor N, et al. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood. 2006;107:257–264.
  • Robak T, Huang H, Jin J, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015;372:944–953.
  • Giebel S, Labopin M, Ehninger G, et al. Association of Human Development Index with rates and outcomes of hematopoietic stem cell transplantation for patients with acute leukemia. Blood. 2010;116:122–128
  • Passweg JR, Baldomero H, Bader P, et al. Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually. Bone Marrow Transplant. 2016;51:786–792.
  • Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–586.
  • Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123:2944–2952.
  • Visco C, Finotto S, Zambello R, et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol. 2013;31:1442–1449.
  • Inwards DJ, Fishkin PA, Hillman DW, et al. Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. Cancer. 2008;113:108–116.
  • Spurgeon SE, Pindyck T, Okada C, et al. Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma. Leuk Lymphoma. 2011;52:1488–1494.
  • Ruan J, Martin P, Shah B, et al. Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma. N Engl J Med. 2015;373:1835–1844.
  • Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24:4867–4874.
  • Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol. 2009; 20:520–525.
  • Kane RC, Dagher R, Farrell A, et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res. 2007;13:5291–5294.
  • Romaguera JE, Fayad LE, McLaughlin P, et al. Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma. Br J Haematol. 2010;151:47–53.
  • Chang JE, Li H, Smith MR, et al. Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). Blood. 2014;123:1665–1673.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.